Skip to main content

Table 1 Patient Characteristics

From: Oral Pirfenidone in patients with chronic fibrosis resulting from radiotherapy: a pilot study

Age Gender Tumor Location Radiation Dose (Gy) Time from Completion of Radiation (Months) ROM Impairment at Baseline Duration of Pirfenidone Treatment (Months)
60 M Head and Neck 63 46.0 Decreased Cervical ROM 25.0
60 M Head and Neck 72 32.1 Decreased Cervical ROM 24.6
54 M Hodgkin's 45 – Pelvis 36 – PA 198.8 Decreased LE ROM and Strength 24.0
59 M Head and Neck 70.2 53.7 Decreased UE and Cervical ROM 23.3
56 M Head and Neck 60 69.1 Decreased UE and Cervical ROM 22.4
53 M Hodgkin's 54 – Mantle 36 – PA 276.5 Decreased Cervical ROM 6.3 (removed from study)
60 M Head and Neck 70 23.4 Decreased Cervical ROM 3.0 (removed from study)